Agilent Technologies, Inc. (A - Free Report) is making every effort to expand presence in life science research space on the back of its strengthening cell analysis offerings and live cell imaging techniques.
This is evident from the latest launch of xCELLigence RTCA eSight, which is a multimode real-time cell analyzer (RTCA). Notably, the new instrument is integrated with xCELLigence biosensor technology, which is considered to be non-invasive. It also features live cell imaging technology.
These two technologies offer label-free, real-time biosensor measurements and kinetic imaging of the same live cell populations.
Agilent’s new RTCA marks the first of its kind which monitors cell health, cytolysis in primary or native cells, morphology and proliferation at predefined temporal resolutions in physiologically relevant environment.
eSight is likely to expand the company’s presence in the research areas – cell biology, immunology, immuno-oncology and immunotherapy.
eSight to Aid Momentum
We believe Agilent is likely to gain traction across researchers involved in real time detailed cell analysis with the help of eSight, which supports a wide range of reporter reagents, various well-plate formats, flexible user-defined schedules and three fluorescence channels.
Moreover, eSight provides unprecedented insight into cellular mechanisms of action and functionality. Further, it offers two vantage points into cell health and responses to a variety of chemical and biological manipulations to scientists and researchers in single experiment.
All these benefits and capabilities of the latest cell analyzer are likely to aid its adoption rate, which in turn will strengthen Agilent’s position in the potential cell analysis market.
Expanding Cell Analysis Portfolio
Agilent’s latest move bodes well for its continued focus toward expanding cell analysis portfolio.
xCELLigence biosensor technology that is contained in eSight was obtained by acquiring ACEA Biosciences. This buyout marked a major step toward bolstering the company’s growth prospects in the rapidly growing cell analysis market.
Further, the company recently entered into a definitive agreement to acquireBioTek Instruments whose product portfolio is includes microplate readers, washers, dispensers, cell imaging systems, automated incubators and stackers. This will strengthen the company’s cell analysis portfolio.
Additionally, buyouts of Seahorse Bioscience and Luxcel Biosciences by the company are acting as tailwinds.
We believe the above-mentioned strong endeavors are expected to aid growth in Agilent’s Life Sciences & Applied Markets Group (LSAG). We note that the segment is the largest contributor, accounting for 46% of fiscal 2018 revenues.
Zacks Rank & Other Stocks to Consider
Currently, Agilent carries a Zacks Ranks #2 (Buy).
Some other top-ranked stocks in the broader technology sector are Ringcentral, Inc (RNG - Free Report) , Garmin Ltd. (GRMN - Free Report) and LogMein, Inc (LOGM - Free Report) . All the three stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Long-term earnings growth rate for Ringcentral, Garmin and LogMeinis currently pegged at 16.32%, 7.35% and 5%, respectively.
Legalizing THIS Could Be Even Bigger than Marijuana
Americans spend an estimated $150 billion in this industry every year… more than twice as much as they spend on marijuana.
Now that 8 states have fully-legalized it (with several more states following close behind), Zacks has identified 5 stocks that could soar in response to the powerful demand. One industry insider described the future as “mind-blowing” – and early investors can still get in ahead of the surge.
See these 5 “sin stocks” now >>